Source: Hwang, et al JAMA Health Forum March 14, 2025 Researchers from the University of Chicago modeled the clinical and financial impact of anti-obesity medications: Zepbound (tirzepatide), Wegovy (semaglutide), and two oral generic drug combinations, phentermine-topiramate and naltrexone-bupropion
isocitrate dehydrogenase, -ketoglutarate dehydrogenase, and succinate dehydrogenase, and at the same time reduced generation of reactive oxygen species stabilized the mitochondrial membrane potential, enhanced the levels of ATP, and enhanced the activity of the mitochondrial complex I [94]
Food and Drug Administration (FDA): FDA Approves Novel Medication for Chronic Weight Management (Zepbound Approval Announcement)
This is one reason transdermal HRT is often preferred when combining with other medications
For patients without insurance coverage, thats a major advantage
Water weight fluctuations can mask fat loss during this period